Recent Approaches to Medicinal Chemistry and Therapeutic Potential of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

Overview

Journal Eur J Med Chem

Specialty Chemistry

Date 2014 Feb 18

PMID 24531198

Citations 24

Authors

Bhumika D Patel

Manjunath D Ghate

Affiliations

Soon will be listed here.

Abstract

Dipeptidyl peptidase-4 (DPP-4) is one of the widely explored novel targets for Type 2 diabetes mellitus (T2DM) currently. Research has been focused on the strategy to preserve the endogenous glucagon like peptide (GLP)-1 activity by inhibiting the DPP-4 action. The DPP-4 inhibitors are weight neutral, well tolerated and give better glycaemic control over a longer duration of time compared to existing conventional therapies. The journey of DPP-4 inhibitors in the market started from the launch of sitagliptin in 2006 to latest drug teneligliptin in 2012. This review is mainly focusing on the recent medicinal aspects and advancements in the designing of DPP-4 inhibitors with the therapeutic potential of DPP-4 as a target to convey more clarity in the diffused data.

Citing Articles

Design, synthesis, biological evaluation and computational studies of 4-Aminopiperidine-3, 4-dihyroquinazoline-2-uracil derivatives as promising antidiabetic agents.

Baziar L, Emami L, Rezaei Z, Solhjoo A, Sakhteman A, Khabnadideh S Sci Rep. 2024; 14(1):26538.

PMID: 39489787 PMC: 11532418. DOI: 10.1038/s41598-024-77481-9.

Exploring Innovative Approaches in Type-2 Diabetes Management: A Comprehensive Review on Nano-carriers and Transdermal Drug Delivery.

Chauhan N, Kumar M, Kumar K, Chopra S, Bhatia A Curr Pharm Des. 2024; 30(22):1725-1745.

PMID: 38847167 DOI: 10.2174/0113816128313325240513113840.

GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review.

Abubakar M, Nama L, Ansari M, Ansari M, Bhardwaj S, Daksh R Curr Top Med Chem. 2024; 24(19):1635-1664.

PMID: 38803170 DOI: 10.2174/0115680266293416240515075450.

Stereochemical insights into β-amino--acylhydrazones and their impact on DPP-4 inhibition.

Reina E, Franco L, Carneiro T, Barreiro E, Lima L RSC Adv. 2024; 14(10):6617-6626.

PMID: 38390500 PMC: 10882265. DOI: 10.1039/d4ra00450g.

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy.

Zlotek M, Kurowska A, Herbet M, Piatkowska-Chmiel I Biomedicines. 2023; 11(11).

PMID: 38002034 PMC: 10669527. DOI: 10.3390/biomedicines11113035.